Targeting refractory prostate cancer: A novel radiopharmaceutical hits the bull’s eye
Researchers have found a new theranostic compound that effectively shrinks prostate tumor in mice. Theranostics is a cancer treatment that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells, by drugs that contain radioactive isotopes. It means that this compound could be a promising option for treating hormone-resistant metastases in patients with recurrent cancers.
Materials provided by Osaka University. Note: Content may be edited for style and length.
Source link aaaaa
